2,147 results on '"MATHEWS, ANNA WILDE"'
Search Results
2. Kaiser Permanente Unit to Acquire North Carolina Hospital System.
3. Medicare Will Recalculate Quality Ratings of Medicare Advantage Plans.
4. Exclusive | NewYork-Presbyterian Hospital System Demanded $25 Million to Stay Out of a Union's Health Insurance Plan.
5. CVS Made a Big Bet on Medicare. It's Looking Risky.
6. UnitedHealth Stock Jumps After Earnings Beat Expectations, Despite Cyberattack.
7. Wegovy: First Medicare Health Plans to Start Paying for Weight-Loss Drug.
8. J&J Accused of Mismanaging Its Employees' Drug Benefits.
9. CVS, Walgreens to Sell Abortion Pill Mifepristone Within Weeks.
10. Cigna Sells Medicare Business to Health Care Service Corp. for $3.3 Billion.
11. Humana Reports Steep Losses, Signals More Trouble for Next Year.
12. Cigna Nears Deal to Offload Medicare Business.
13. CVS Plans to Overhaul How Much Drugs Cost.
14. Cigna, Humana in Talks for Blockbuster Insurance Merger in Stock-and-Cash Deal.
15. Health Inflation's Big Hike This Year, in Charts.
16. Pharmacy Giant Walgreens Names Tim Wentworth as New CEO.
17. These Employers Took On Healthcare Costs, and the Fight Got Nasty.
18. Covid Boosters Aren't Reaching People Who Want Them.
19. Health-Insurance Costs Are Taking Biggest Jumps in Years.
20. Bayer is asked to suspend Trasylol sales
21. Novartis drug approved by EU
22. Sequel for Vioxx critic: attack on diabetes pill; Glaxo shares plunge as Dr. Nissen sees risk to heart from Avandia
23. Sanofi's bird-flu vaccine is granted FDA approval: first human treatment is seen as stopgap aid as research continues
24. Sleep drugs get warning on labels sought by FDA
25. Firms study drugs to help avert diabetes
26. Reading fine print, insurers question studies of drugs
27. A death prompts withdrawal of promising MS drug; are too many unproven drugs receiving FDA early approval? Process comes under scrutiny
28. Merck, Pfizer face advertising obstacle; if Vioxx, Celebrex return, the drugs' promotion will be a difficult task
29. FDA panel weighs array of options on painkillers
30. Painkiller panel gets few answers; drug makers, researchers fail to agree on the risks, proper use of the medicine
31. Why U.S., Canada differ on safety of attention-deficit drug
32. FDA Safety Office, FCC to get boost as SEC funding is stable
33. Second opinion: as drug safety concerns grow, looking overseas for solutions
34. U.S. plans broad painkiller review; health officials to focus on side effects, with eye toward regulatory action
35. Celebrex drama may finally prompt changes at the FDA
36. As safety issues hit Celebrex, Pfizer decides to hang tough; drug giant will halt ads, but continue selling its widely used painkiller
37. Medical journal seeks FDA overhaul
38. FDA official assails agency on monitoring of risks; at hearing on Vioxx recall, safety expert cites lapses, and points to other drugs
39. Merck documents show Vioxx tension
40. Did FDA staff mimize Vioxx's red flags?
41. FDA plans major review of procedures
42. E-mails suggest Merck knew Vioxx's dangers at early stage; as signs of heart risk rose, officials played hardball; trainees are told 'dodge'
43. New Vioxx study projects cases of heart attacks
44. Vioxx recall raises questions on FDA's safety monitoring
45. Expiration date: Merck pulls Vioxx from market after link to heart problems; drug's demise raises concerns about company's future; loss of $2.5 billion in sales' patients are left in quandary
46. FDA will warn on antidepressants; labels will say the drugs increase youth suicide risk; 'black box' alert considered
47. Congress to air controversies over drug trials
48. Big HMO reconsiders Vioxx after study points to heart risks
49. FDA wll seek to revise Labels for antidepressants
50. Medicare battle causes headaches; proposed drug guidelines to intensify industry fight; manufacturers vs. insurers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.